Listen to the episode on a streaming platform by clicking one of the links below:

• Listen on Spotify

• Listen on Apple Podcasts

• Q1 earnings from the four largest publicly traded hospital operators—HCA, Tenet, UHS, and CHS—showed soft headline volumes, but the softness was a mix of one-offs (shorter flu season, winter storms) layered on top of the predicted decline due to the expiration of ACA enhanced premium tax credits.

  • The weather and respiratory effects are temporary, but the payer mix erosion from exchange losses is permanent and expected to worsen through 2026.

  • High-acuity outpatient migration is now the dominant capital story, with all four operators leaning hard into ASC acquisitions and de novos.

  • The most striking takeaway is what the calls didn't dwell on: OBBBA barely came up, even as many nonprofit health system boards have made it the dominant frame for 2026 strategy. The for-profits are betting that commercial mix and balance sheet strength make Medicaid policy impact less existential.

• UnitedHealthcare announced it will eliminate prior authorization for roughly 30% of services requiring advance approval by year-end—with an emphasis on outpatient services—paralleling similar pledges from other major payers as part of a voluntary commitment with HHS and CMS.

  • Whether this is substantive or PR depends on what's actually on the list, which has not yet been disclosed. A previously announced rural provider carve-out may matter more, given how much rural hospitals with thin margins stand to gain from reduced administrative burden.

  • By easing friction on outpatient services while leaving inpatient utilization management intact, UHC is widening the administrative gap between settings—sharpening the strategic pressure on health systems around ambulatory capacity and ASC investment, and giving physicians yet another reason to prefer working outside the hospital.

• CMS recently proposed CJR-X, a mandatory nationwide bundled payment model for lower extremity joint replacement taking effect October 1, 2027—extending the original CJR model’s two-sided risk structure to most IPPS hospitals.

  • The savings playbook still runs through post-acute spend, but the easy reductions have largely been harvested. CMS itself acknowledges this by trimming the target price discount from 3% to 2%. For systems where post-acute utilization has already structurally shifted, CJR-X is less a savings opportunity than a downward adjustment to LEJR economics they'll need to offset elsewhere.

  • Paired with TEAM, CJR-X signals that CMS has validated a template it's likely to keep using: mandatory episode pricing on high-volume, high-cost procedures, with regional benchmarks engineered to extract savings from whatever lever is available.

• Delays in HHS processing of J-1 visa waivers threaten to force hundreds of foreign-trained physicians out of the U.S. by a July 30 deadline, jeopardizing placements in designated provider shortage areas. The pressure compounds a separate $100K H-1B visa fee hike that has already caused 64% of AHA member hospitals to limit or pause foreign physician recruitment.

  • The impact will fall hardest on the systems least able to absorb it—rural providers, safety-net systems, and those with heavy Medicaid mix—and will worsen access in the specialties J-1 waivers are reserved for (primary care, pediatrics, OB/GYN, behavioral health), which also happen to be the upstream referral channels and relationship-builders that health systems can least afford to lose.

  • Advocacy and litigation are the likeliest paths to resolution, but neither moves quickly: three lawsuits and a bipartisan fee exemption bill are all stalled, and election-year politics make standalone action unlikely. The recent quiet reversal of the physician travel ban after coordinated pressure from AHA, AMA, NRHA, and state AGs offers a template—but only if stakeholders mobilize before the deadline.

• CMS Administrator Mehmet Oz directed all 50 state Medicaid directors to revalidate program providers, expanding a fraud crackdown that had previously focused on Democratic-led states.

  • Beyond the immediate compliance push, the initiative may also serve a broader narrative purpose: reinforcing concerns about Medicaid integrity in ways that could support future spending reductions.

  • The audits could squeeze the smaller partners health systems depend on, whose thinner margins and limited compliance infrastructure leave them more exposed.

Listen to the episode on a streaming platform by clicking one of the links below:

• Listen on Spotify

• Listen on Apple Podcasts

• This year’s Spring CSO Forum sparked some thought-provoking debates about the future of healthcare and the changes that health systems will need to make to keep pace. Today’s newsletter highlights five big ideas from a dozen closed-door sessions:

  • AI-generated health advice might already be impacting care volumes—and raising existential questions about capital expenditures that need to pay off over decades.

  • Federal policymakers see 340B reform as a potential pay-for in behind-the-scenes negotiations with pharma lobbyists.

  • Keeping your brand name off ASCs can have surprising strategic advantages, especially for health systems expanding outside of their primary service area.

  • Health systems are giving physicians equity in ASCs—but some draw the line at employed physicians.

  • Many younger consumers don’t want a traditional primary care relationship, but alternatives like virtual-first care come with their own trade-offs.

• CVS is opening new smaller-footprint stores in urban markets that ditch the aisles of snacks and home goods in favor of a pharmacy-only model.

  • This could help the company target Medicaid and dual-eligible populations and has implications for health system 340B savings.

  • While the chain continues its focus on healthcare, the emphasis on pharmacy services could reflect a “back-to-basics” mindset as other parts of the company’s healthcare flywheel struggle.

• Amazon and Walmart both just launched weight management programs centered on GLP-1 access, but with very different strategies: Amazon integrates prescribing with its own One Medical clinics and Amazon Pharmacy delivery, while Walmart stays "asset-light" by routing patients to third-party app-based partners and just handling pharmacy fulfillment.

  • Amazon's offering is the bigger competitive threat to health systems because it directly mimics comprehensive primary care, while Walmart's approach signals a retreat from running clinics toward betting that the pharmacy counter—not the exam room—is where physical retailers can win.

• Baylor Scott & White is shutting down its Medicaid and ACA Marketplace health plans by year-end, dropping 225K members—Medicaid because Texas only awarded it a contract in Lubbock (where it has no hospitals), and Marketplace because of complexities tied to expiring enhanced federal premium tax credits.

  • The exit highlights how risky Medicaid managed care can be for regional plans: a single state procurement cycle wiped out most of its market share overnight.

  • BSW likely won't be the last small or provider-sponsored plan to retreat from the ACA Marketplace in 2027.

• CMS approved 150+ companies for its new ACCESS chronic care model (including Headspace, Verily, Whoop, and Withings), but the more telling story is who passed: only 22 of 68 publicly interested digital health companies submitted applications, suggesting the economics don't work for many.

  • The participants who joined tend to have a built-in edge—they either own hardware, are using ACCESS as a cheap Medicare distribution channel, or are restructuring their business around it—while pure-services AI players like Sword Health passed.

Listen to the episode on a streaming platform by clicking one of the links below:

• Listen on Spotify

• Listen on Apple Podcasts

We dig into how St. Charles Health System, a four-hospital not-for-profit in Central Oregon and the sole major provider across a 32,000-square-mile service area, went from seven Medicare Advantage payers down to one and then turned a twenty-year track record of clinical quality into a negotiating tool that cut cancer treatment authorization times from weeks to a single day.

Matt Swafford, CFO, and Mark Hallett, Chief Clinical Officer, walk us through the decision to terminate contracts with six national MA payers, how they used NCCN concordance rates to negotiate instant authorization with PacificSource, and the CFO-CCO partnership model that enabled it all.